

1 **Title:** The further development of cold plasma technology: The effectiveness of a
2 contactless, indirect atmospheric cold plasma method for germ reduction on surfaces in
3 vitro and in vivo

4

5 **Authors:** Ulrich Schmelz¹, Tom Schaal², Gilbert Hämmerle³, Tim Tischendorf*²

6 ¹ University of Fulda, Fulda, Germany

7 ² Faculty of Health and Healthcare Sciences, University of Applied Sciences Zwickau,
8 Zwickau, Germany

9 ³ DGKP, ZWM, AZWM, Head of Wound Outpatient Clinic LKH Bregenz

10 *Corresponding author: Tim Tischendorf (TT), E-Mail: tim.tischendorf@fh-zwickau.de, Tel.:
11 +49 375 5363407

12

13 **Authors' Contributions:**

14 US: Writing – original draft; Formal Analysis; Investigation; Project administration;
15 Conceptualization

16 TS: Writing – original draft; Formal Analysis; Writing – review & editing

17 GH: Writing – original draft; Writing – review & editing

18 TT: Writing – original draft; Visualization; Data curation

19 **Abstract**

20 This study investigates the antimicrobial potential of an indirect cold plasma method for the
21 treatment of wounds. Indirect plasma methods differ from direct methods in that the cold
22 plasma does not come into direct contact with the surface to be treated. The indirect plasma
23 method described here has been implemented in the PLASMOHEAL device. The device
24 generates an aerosol of liquid particles, which is conditioned with plasma reaction products
25 and passed over the areas to be treated without contact. In vitro tests show a significant
26 germ reduction of 3.4 to 4.5 log levels against various microorganisms. In vivo tests on
27 volunteers demonstrate a reduction in E. coli contamination of 4.06 to 5.15 log levels. These
28 results show that indirect plasma methods can achieve equivalent effects to direct methods.
29 The highly effective, pain-free treatment at moderate costs make the indirect plasma
30 method a promising option in modern wound care.

31

32 **Keywords**

33 Cold plasma; Wound treatment; Chronic wounds; Germ reduction

34

35 **Introduction**

36 What is a physical "plasma"?

37 "Plasma" in the sense of the physical definition, represents the state of a conductive gas.

38 In the plasma state, a gas that is practically non-conductive under normal conditions is
39 partially ionized by an ignition pulse. The gas ions are then electrically charged particles,
40 whereby the gas assumes the state of an ionic conductor (2nd order conductor). This state
41 is maintained by a further supply of electrical energy.

42 The ionization of gas molecules leads to a transfer of electrical energy to the gas molecules.

43 The ionized gas molecules can transfer this energy, for example to surfaces. As a result,
44 surfaces or even liquids or the surrounding air can be modified [1].

45 Plasma can occur at atmospheric, elevated or reduced pressure. Plasma can also be
46 altered by the addition of heat energy [2]. Furthermore, plasmas are classified according to

47 the reacting gases; in the process currently under consideration, oxygen and water vapor
48 are brought to react as reactants in the plasma.

49 The process considered in this paper takes place at room temperature and atmospheric
50 pressure, hence the term 'atmospheric cold plasma'. The gas used for the plasma reactions
51 is ambient air, which contains approximately 21 percent oxygen and water vapour up to the
52 (temperature-dependent) condensation limit. Accordingly, the ambient air supplies the
53 gases (oxygen and water vapor), which are required for the plasma reaction [3]. Plasma
54 reactions can be direct or indirect reactions (Figure 1).

55

56 <<Figure 1. Forms of plasma reactions: direct and indirect plasma reactions.>>

57

58 Until 2024, published studies have primarily documented direct plasma procedures or a
59 combination of direct and indirect procedures in the field of wound sanitation [4]. The
60 antimicrobial effect of indirect cold plasma methods on surfaces was basically shown in
61 2024 [5]. In a direct plasma reaction, the direct contact of the plasma with a surface leads
62 to a modification of this surface. Energy is only required for the plasma reaction (Figure 1:
63 direct method: step 1 + step 2; indirect method: step 1). Direct methods are operating in
64 consideration of the surface. So direct plasma reactions are in contact to the surface needs
65 to treat.

66 Additional steps are found with indirect plasma methods. In the case of indirect plasma
67 reactions, additional steps are added that decouple the plasma reaction from the surface
68 to be treated. Due to decoupling, the plasma reaction always takes place at a distance from
69 the surface to be treated. This means that the energy required for the plasma reaction can
70 be outsourced to an external device (Figure 1: step 1; indirect method).

71 In an indirect plasma reaction, the process takes place outside the relevant surface. Such
72 an indirect plasma method is used, for example, in the "PLASMOHEAL" device (WK-
73 MedTec GmbH, Bückeberg). The device produces the cold plasma reaction products,
74 primarily hydroxyl radicals, which are generated by a targeted flow of ambient air via a

75 corresponding plasma source [3]. These are generated on the basis of the defined potential
76 difference (voltage; here: 1.45 kV as the effective value of the alternating voltage), the
77 frequency (38 kHz) and the frequency form (sinusoidal frequency). Ozone is only present
78 in very small traces.

79 Then distilled water is nebulized using an ultrasonic module. Ambient air which has been
80 enriched by cold plasma products activate the nebulized water to a cold plasma aerosol
81 (CAP). The plasma reaction products of the air lead to an increase in the electrophysical
82 potential of the nebulized liquid without any material change [2] (Figure 2).

83 The aerosol is then passed over the areas to be disinfected (here: skin, in particular
84 wounds) for three minutes at a distance of 7.5 cm.

85

86 <<Figure 2. Functional diagram of an indirect cold plasma method using the example of
87 PLASMOHEAL. Note. Distilled water is used as the process water for aerosol formation.
88 4.5 liters of aerosol contain 1 mL of process water as an aerosol component.>>

89

90 Effect of direct and indirect plasma methods against microorganisms on surfaces:

91 Both direct and indirect plasma methods are surface-active methods. This focuses on the
92 transient flora, which is preferably found on the surface of the skin, mucous membranes or
93 wounds, while the resident flora (local flora, microbiome) is also localized in deeper layers.

94 The plasma reaction products are effective on the surface of the skin and therefore not in
95 the tissue. In the case of wounds, the surface is interrupted so that the method could also
96 be effective in the contact area of the aerosol in superficial horny layers.

97 Cold plasma products (contain in aerosols or in direct reaction) support the disruption of
98 the redox processes of microorganisms. Specifically, a "short circuit" of the cell membrane
99 occurs, which leads to a collapse of the resting potential between the extracellular and
100 intracellular space, whereby all transmembrane transport processes in the microorganism
101 are damaged and the microorganism is destroyed [4]. As a result, there is generally no

102 longer any potential for infection. The shown short circuit can be described as a "selective
103 short circuit", as the human cells are practically not affected (Figure 3).

104

105 <<Figure 3. Cold plasma eliminates microorganisms by a short circuit of the membrane
106 potential.>>

107

108 Absence of toxicological effects on human tissues and cells:

109 The effects occurring in microorganisms are not observed in higher organisms.

110 Toxicologically relevant samples or by-products are not found in indirect plasma processes

111 [6]. To substantiate this, toxicity assessments can provide support. As an example, toxicity

112 tests such as the Ames test (according to EN ISO 10993-3) and a cytotoxicity test

113 (according to EN ISO 10993-5) were performed for the CAP on which the device is based.

114 Both assessments showed the absence of mutagenic effects in human cells. Furthermore,

115 no adverse effects were observed with multiple clinical applications of direct cold plasma

116 systems in wound treatment. The presence of antioxidant enzymes (catalase, superoxide

117 dismutase, alpha-1-antitrypsin) in tissues and organisms that effectively neutralize plasma

118 reaction products before damage to the cell membrane of tissue cells is assumed [6]. It is

119 important to note that there are no recognizable acute or chronic toxic effects on higher

120 organisms (eukaryotic tissues: plants, animals, humans). This lack of effect can be

121 attributed to the presence of beforehand mentioned antioxidant enzymes (catalase,

122 superoxide dismutase, alpha-1-antitrypsin) in these tissues and organisms [6].

123 Hence, the indirect plasma process appears to be able to eliminate microorganisms without

124 harming humans, thereby reducing the risk of infection, which has already been proven in

125 comparison with direct plasma processes.

126

127 Proof of efficacy of direct plasma methods in the field of wound rehabilitation:

128 A germ-reducing effect of the direct plasma is generally recognized. In studies in vivo (on

129 18 patients), a reduction of germs in the wound was observed in swabs, regardless of the

130 localization and size of the wound, as well as previous illnesses and cofactors (e.g. tobacco
131 abuse, cardiovascular diseases) [7].

132 In this study, microbiocidal activity against both Gram-positive cocci bacteria and Gram-
133 negative rod bacteria (both groups include the most common human infectious agents) is
134 sufficiently demonstrated. At the same time, Daeschlein et al. have shown that there are
135 no differences in potency regarding inhibitor-resistant variants of certain microorganisms
136 (e.g. MRSA, MRGN). The microorganism is damaged "in toto" by the electrophysical
137 reaction, which means that a mutation of metabolic pathways has no influence on the
138 microbiocidal potency [7]. Furthermore, Zimmermann et al. describe an in vitro virucidal
139 effect against adenoviruses in the range of approximately 3 log levels [8].

140 The evaluation of the results of Daeschlein et al. and Zimmermann et al. leads to the
141 conclusion that a microbiocidal effect of > 3 log levels can be expected from the direct
142 plasma methods.

143 The germ-reducing effect is also indirectly demonstrated by the observation that the pH
144 value of the wound drops when treated with direct cold plasma methods. The typical
145 bacterial wound infection pathogens result in an increase in the pH value of the wound to
146 a range of 8 to 10. The subsequent killing of these alkalizing microorganisms as a result of
147 the cold plasma method then brings about the pH reduction required for optimal wound
148 healing [9].

149 In addition, a considerable acceleration of wound healing was observed with the use of
150 direct plasmas [10; 11; 12; 13, 14].

151 According to Strohhal et al. 2022, it is shown that wounds treated with plasma products
152 have a higher probability of healing (approx. 60 per cent higher compared to supportive
153 therapy alone). The individual localization and genesis of the wound is practically irrelevant.
154 Furthermore, application studies with immunological skin diseases (using the example of
155 rosacea) have shown that the method is also forward-looking in the treatment of such
156 immunological diseases [15]. Finally, it should be noted that the claimed effectiveness of
157 the direct methods can be attributed to the antimicrobial effect. The studies of the

158 effectiveness of the direct methods would therefore also be applicable to the indirect
159 methods.

160

161 Derivation of the research question:

162 The antimicrobial potential of the CAP could be used for specialized disinfection, for
163 example of wounds. The cold plasma disinfection methods for wounds used to date - with
164 acceptable results - are almost exclusively direct-acting methods with a direct plasma jet
165 or plasma field. If an equivalent microbiocidal efficacy of indirect plasma methods to direct
166 plasma methods can be demonstrated, it can be concluded that indirect plasma methods
167 also have an equivalent effect in the field of wound decontamination.

168 This leads to the following research question: Does the indirect cold plasma process have
169 at least an equivalent antimicrobial effect compared to direct cold plasma processes?

170 To provide this proof, the microbiocidal efficacy of an indirect plasma method is tested in
171 vitro and in vivo in accordance with existing test standards.

172

173 **Methods**

174 Methodology of *in vitro* testing of the microbiocidal effect:

175 An in vitro test of the germ reduction performance against five normatively defined
176 microorganisms (Staph. aureus ATCC 6538, Staph. epidermidis ATCC 14990, E. coli
177 NCTC 19538, Pseudomonas aeruginosa ATCC 10145, Candida albicans ATCC 10321,
178 BS) was carried out in accordance with DIN spec. 91315:2014. The identity of the test
179 organism was checked by using Gram staining in conjunction with transmitted light
180 microscopy and by determining the metabolic performance of the test organism in relation
181 to various substrates. Furthermore, the test organism was identified as indole-forming from
182 tryptophan (indole-positive). The universal medium Caso agar in 60 mm Petri dishes was
183 used as a culture medium for cultivating the inoculates of the samples. After checking their
184 identity, the microorganisms were cultivated as a surface culture and washed with sterile
185 and pyrogen-free NaCl solution 0.9 per cent to obtain a microbial suspension with a turbidity

186 corresponding to McFarland Standard eight. The germ suspensions were then applied to
187 stainless steel test specimens (100*10*1mm) with a roughness depth of 100µm using a
188 sterile swab. The stainless steel test specimens were prepared by immersion for five
189 seconds in the test germ suspension, draining and air drying for two hours. These prepared
190 test specimens were then exposed to the PLASMOHEAL process. The test specimen was
191 exposed to the aerosol of the device for three minutes. The microorganisms were then
192 washed off by resuspending them in 10 mL of sterile and pyrogen-free NaCl solution 0.9
193 per cent in a sterile test tube by shaking for 30 seconds using a VORTEX 3 shaker. From
194 this suspension (undiluted, dilution factor therefore 10⁰) a geometric dilution series (in
195 powers of ten) up to 10⁻³ is created. A volume of 0.1 mL is taken from each dilution stage
196 and applied to the culture medium suitable for the respective test organism. The volume of
197 0.1mL is homogeneously distributed on the culture medium using a Drigalski spatula
198 (Figure 4).

199

200 <<Figure 4. Overview geometric dilution row.>>

201

202 In parallel, an untreated test specimen is also analyzed for each test organism (Table 1).

203 Table 1. Microorganisms used for the in vitro test in accordance with DIN spec. 91315.

Microorganisms	Germ identification	Culture media with identification number	Incubation time and temperature
Staphylococcus aureus	ATCC 6538	Mannitol-salt-agar No.1050	48h / 36°C
Staphylococcus epidermidis	ATCC 14990	Caso-agar No. 4020	48h / 36°C
Escherichia coli	NCTC 19538	Colichromer-agar No. 4028	48h / 36°C
Pseudomonas aeruginosa	ATCC 10145	Cetrimid-agar No. 4025	48h / 36°C
Candida albicans	ATCC 10321	Sabouraud-agar 2% No. 4130 ¹	72h / 28°C

Note. ¹The microbiological culture media for this analysis were obtained from Dr. Möller & Schmelz, Göttingen, Germany.; ATCC = American Type Culture Collection. NCTC = National Collection of Type Cultures.

204

205 After the incubation time required for the respective test germ in the incubator, the colonies
206 of the culture medium of the dilution stage containing ten to 100 colonies are counted.

207 Considering the dilution level, the fact that 0.1mL of 10mL per dilution level was applied to
208 the culture medium and the initial volume of 10mL (in which the washout took place), the
209 bacterial count per test specimen is calculated. After forming the decadic logarithm of the
210 bacterial count, the log of the bacterial count after exposure is subtracted from the logarithm
211 of the bacterial count without exposure. This is used to calculate the log reduction factor,
212 which indicates by how many powers of ten an initial bacterial load is reduced by the
213 method under consideration.

214

215 Methodology of *in vivo* testing of the microbiocidal effect:

216 Based on the results of the *in vitro* test, the germ reduction performance was tested in the
217 *in vivo* test in accordance with EN 1500 using the test germ Escherichia coli K12. EN 1500
218 is used for microbiocidal testing of hand sanitizers and therefore allows *in vivo* testing on
219 test subjects. The EN 1500 standard on which the test is based describes the wetting of
220 the fingertips as the location of the wash-off, because these can be mobilised mechanically
221 by rubbing with the opposing thumb. The hands were immersed in the test germ suspension
222 for five seconds in the area of the fingers, then drained and loaded with the test germ for
223 three minutes. Before and after application of the PLASMOHEAL method, the bacterial
224 count of the skin of the hands was methodically determined in accordance with EN 1500,
225 with both hands contaminated by the bacterial suspension in the area of the fingers. The
226 "pre-value" without the use of the device was determined from the left hand, then the right
227 hand was exposed to the aerosol in the area of the contaminated fingers for three minutes.
228 The "after value" was then determined from the exposed right hand. The dilution series and
229 cultivation were carried out analogue to the method described above for the *in vitro* test of
230 the microbiocidal effect. After cultivation and evaluation, the log reduction factor of the cold
231 plasma process when applied to human skin was determined. For evaluation, the test result
232 of the PLASMOHEAL method was compared with the log reduction factor of standard
233 alcohol as a reference method following the analogy of EN 1500.

234 EN 1500 specifies E. coli K12 as the test germ, as this microorganism is apathogenic (it is
235 also a natural commensal of the human colon, among other things) and furthermore its
236 tenacity (resistance to inactivation) includes sufficient obligate pathogenic germs, E. coli is
237 a sufficient disinfection surrogate and at the same time there is no infectiological risk. E.
238 coli on the hand is therefore used as a surrogate for a contaminated wound. Therefore, the
239 performance of the disinfection efficacy test is not a clinical test in the sense of requiring
240 approval by an ethics committee. Rather, this test is a standard procedure, i.e. "state of the
241 art or science", which is required according to EN 1500 in order to determine the
242 aforementioned disinfection efficacy in a technically reproducible manner. The test is
243 carried out in this form many times a day in Germany.

244 The test subjects have declared to the person carrying out the test that the test is voluntary,
245 furthermore there are no direct dependencies, and the test subjects also declared that they
246 were not, did not want to be, or could not be pregnant. We confirm that all methods of this
247 study were conducted in accordance with the relevant guidelines and regulations. The
248 participants have given their informed consent to participate in the study in advance.
249 Written informed consent to participate was obtained from the participants. The consents
250 were documented in a standardized laboratory list and signed by the participants. No
251 minors were included. A written exemption from ethics approval was obtained from the
252 institutional review board, as the test was carried out in accordance with the requirements
253 of the EN 1500 test standard and its effectiveness was confirmed in laboratory tests.

254

255 **Results**

256 The aim of this study is to investigate the germ-reducing effect of the PLASMOHEAL
257 process both in vitro and in vivo. By analyzing in detail the results of the in vitro tests on the
258 germ-reducing effect of the PLASMOHEAL procedure (Table 2) and the in vivo tests (Table
259 3), the dynamic effect of this innovative wound treatment method is comprehensively
260 examined. The germ-reducing properties of the procedure are presented in detail at various
261 levels of testing.

262 Table 2. Results of the in vitro test of the germ-reducing effect of the PLASMOHEAL
263 process.

No.	V1	V2	CfU/ Agar plate	CfU/ Approach	Dilution	CfU/ Proband	Log CfU/ Proband	Log Reductions faktor
Staphylococcus aureus 3min:								
1.1.A-3	10,0 mL	0,1 mL	87	8,700	10,000	87,000,000	7.94	
1.1.B-3	10,0 mL	0,1 mL	28	2,800	1	2,800	3.45	4.49
1.2.A-3	10,0 mL	0,1 mL	56	5,600	10,000	56,000,000	7.75	
1.2.B-3	10,0 mL	0,1 mL	26	2,600	1	2,600	3.41	4.33
1.3.A-3	10,0 mL	0,1 mL	78	7,800	10,000	78,000,000	7.89	
1.3.B-3	10,0 mL	0,1 mL	22	2,200	1	2,200	3.34	4.55
Staphylococcus epidermidis 3min:								
1.1.A-3	10,0 mL	0,1 mL	56	5,600	10,000	56,000,000	7.75	
1.1.B-3	10,0 mL	0,1 mL	31	3,100	1	3100	3.49	4.26
1.2.A-3	10,0 mL	0,1 mL	44	4,400	10,000	44,000,000	7.64	
1.2.B-3	10,0 mL	0,1 mL	25	2,500	1	2,500	3.40	4.25
1.3.A-3	10,0 mL	0,1 mL	76	7,600	10,000	76,000,000	7.88	
1.3.B-3	10,0 mL	0,1 mL	37	3,700	1	3,700	3.57	4.31
Escherichia coli 3min:								
1.1.A-3	10,0 mL	0,1 mL	92	9,200	10,000	92,000,000	7.96	
1.1.B-3	10,0 mL	0,1 mL	54	5,400	1	5,400	3.73	4.23
1.2.A-3	10,0 mL	0,1 mL	78	7,800	10,000	78,000,000	7.89	
1.2.B-3	10,0 mL	0,1 mL	34	3,400	1	3,400	3.53	4.36
1.3.A-3	10,0 mL	0,1 mL	65	6,500	10,000	65,000,000	7.81	
1.3.B-3	10,0 mL	0,1 mL	39	3,900	1	3,900	3.59	4.22
Pseudomonas aeruginosa 3min:								
1.1.A-3	10,0 mL	0,1 mL	72	7,200	10,000	72,000,000	7.86	
1.1.B-3	10,0 mL	0,1 mL	26	2,600	1	2,600	3.41	4.44
1.2.A-3	10,0 mL	0,1 mL	61	6,100	10,000	61,000,000	7.79	
1.2.B-3	10,0 mL	0,1 mL	34	3,400	1	3,400	3.53	4.25
1.3.A-3	10,0 mL	0,1 mL	93	9,300	10,000	93,000,000	7.97	
1.3.B-3	10,0 mL	0,1 mL	45	4,500	1	4,500	3.65	4.32
Candida albicans 3min:								
1.1.A-3	10,0 mL	0,1 mL	78	7,800	10,000	7,800,000	6.89	
1.1.B-3	10,0 mL	0,1 mL	31	3,100	1	3,100	3.49	3.40
1.2.A-3	10,0 mL	0,1 mL	59	5,900	10,000	59,000,000	7.77	
1.2.B-3	10,0 mL	0,1 mL	27	2,700	1	2,700	3.43	4.34
1.3.A-3	10,0 mL	0,1 mL	86	8,600	10,000	86,000,000	7.93	
1.3.B-3	10,0 mL	0,1 mL	29	2,900	1	2,900	3.46	4.47

264 Note. No. = Identification of the test run, where the first two digits stand for the test person number and 'A' =
265 test run before disinfection (initial bacterial count), 'B' = test run after disinfection (initial bacterial count); V1 =
266 Total volume Approach to leaching; V2 = Volume of the batch from V1, which was applied to the agar plate;
267 CfU = Colony forming Unit.
268

269 Table 3. Results of the in vivo test of the germ-reducing effect of the PLASMOHEAL
270 process.

No.	V1	V2	CfU/Agar plate	CfU/ Approach	Dilution	CfU/ Proband	Log CfU/ Proband	Log Reductions factor	Mean Values Log RF
01 before	10.0 mL	0.1 mL	46	4,600	10,000	46,000,000	7.66		
01 after	10.0 mL	0.1 mL	3	300	1	300	2.48	5.19	5.19
02 before	10.0 mL	0.1 mL	18	1,800	10,000	18,000,000	7.26		
02 after	10.0 mL	0.1 mL	5	500	1	500	2.70	4.56	4.56
03 before	10.0 mL	0.1 mL	16	1,600	100,000	160,000,000	8.20		
03 after	10.0 mL	0.1 mL	14	1,400	1	1400	3.15	5.06	5.06
04 before	10.0 mL	0.1 mL	23	2,300	1,000	2,300,000	6.36		
04 after	10.0 mL	0.1 mL	2	200	1	200	2.30	4.06	4.06
05 before	10.0 mL	0.1 mL	84	8,400	10,000	84,000,000	7.92		
05 after	10.0 mL	0.1 mL	5	500	1	500	2.70	5.23	5.23
06 before	10.0 mL	0.1 mL	15	1,500	10,000	15,000,000	7.18		
06 after	10.0 mL	0.1 mL	3	300	1	300	2.48	4.70	4.70
07 before	10.0 mL	0.1 mL	4	400	10,000	400,000	6.60		
07 after	10.0 mL	0.1 mL	1	100	1	100	2.00	4.60	4.60
08 before	10.0 mL	0.1 mL	92	9,200	10,000	92,000,000	7.96		
08 after	10.0 mL	0.1 mL	17	1,700	1	1700	3.23	4.73	4.73
09 before	10.0 mL	0.1 mL	39	3,900	10,000	39,000,000	7.59		
09 after	10.0 mL	0.1 mL	5	500	1	500	2.70	4.89	4.89
10 before	10.0 mL	0.1 mL	24	2,400	10,000	24,000,000	7.38		
10 after	10.0 mL	0.1 mL	1	100	1	100	2.00	5.38	5.38
11 before	10.0 mL	0.1 mL	17	1,700	10,000	17,000,000	7.23		
11 after	10.0 mL	0.1 mL	5	500	1	500	2.70	4.53	4.53
12 before	10.0 mL	0.1 mL	11	1,100	10,000	11,000,000	7.04		
12 after	10.0 mL	0.1 mL	1	100	1	100	2.00	5.04	5.04
13 before	10.0 mL	0.1 mL	26	2,600	10,000	26,000,000	7.41		
13 after	10.0 mL	0.1 mL	2	200	1	200	2.30	5.11	5.11
14 before	10.0 mL	0.1 mL	14	1,400	10,000	14,000,000	7.15		

14 after	10.0 mL	0.1 mL	4	400	1	400	2.60	4.54	4.54
15 before	10.0 mL	0.1 mL	14	1,400	10,000	14,000,000	7.15		
15 after	10.0 mL	0.1 mL	1	100	1	100	2.00	5.15	5.15
16 before	10.0 mL	0.1 mL	39	3,900	10,000	39,000,000	7.59		
16 after	10.0 mL	0.1 mL	9	900	1	900	2.95	4.64	4.64
17 before	10.0 mL	0.1 mL	21	2,100	10,000	21,000,000	7.32		
17 after	10.0 mL	0.1 mL	3	300	1	300	2.48	4.85	4.85
18 before	10.0 mL	0.1 mL	14	1,400	10,000	14,000,000	7.15		
18 after	10.0 mL	0.1 mL	4	400	1	400	2.60	4.54	4.54
							Mean value log RF	4.82	
							Median log RF	4.79	
Comparison control with standard alcohol according to EN 1500 (60% n-propanol, 40% water)									
19 before	10.0 mL	0.1 mL	9	900	10,000	9,000,000	6.95		
19 after	10.0 mL	0.1 mL	1	100	1	100	2.00		
19 after	10.0 mL	0.1 mL	3	300	1	300	2.48		
19 after	10.0 mL	0.1 mL	1	100	1	100	2.00		
19 after	10.0 mL	0.1 mL	4	400	1	400	2.60		
19 after	10.0 mL	0.1 mL	2	200	1	200	2.30	2.28	4.68

Note. No. = Identification of the test run; V1 = Total volume Approach to leaching; V2 = Volume of the batch from V1, which was applied to the agar plate; CfU = Colony forming Unit; RF = Reduction factor.

271

272 Discussion

273 The results obtained show a microbiocidal reduction performance of the PLASMOHEAL
274 process tested in vitro against the test germs Staph. aureus, Staph. epidermidis, E. coli,
275 Pseudomonas aeruginosa and Candida albicans of 3.4 to 4.5 log levels. When considering
276 the reduction factors of all five microorganisms tested, a mean value of 4.28 and a median
277 of 4.32 log levels were calculated.

278 The tested method thus achieves a germ reduction of > 4 powers of ten, which corresponds
279 to a reduction in the germ count density of > 99.99 percent.

280 The in vivo test with E. coli in accordance with EN 1500 was carried out on the real skin of
281 the test subjects. Due to the similarity in bacterial colonization between skin and wounds,
282 the skin can be regarded as a surrogate for wound testing [16]. A reduction of the initial E.
283 coli contamination in the range between 4.06 and 5.15 log levels was determined. The
284 mean value of log reduction factor across the results of the 18 test subjects was 4.82 log
285 levels, while the median of this group of values was determined to be 4.79 log levels.

286 The targeted reduction of microorganisms is an important method of disinfection.
287 Disinfection describes an antiseptic process that leads to a state of asepsis and is
288 characterized by the fact that the risk of infection is largely eliminated. This is achieved by
289 reducing the density of microorganisms, which is so low after disinfection that an infection
290 is unlikely [17].

291 The German Association for Applied Hygiene (VAH) initially recommends the highest
292 possible germ reduction. At least 3 log levels are considered necessary as a quantitative
293 value for germ reducing processes. Depending on the measure and the purpose of use, 4
294 to 5 log levels are required [18].

295 The PLASMOHEAL process shows a reduction of 4.28 log levels against the test germs
296 Staph. aureus, Staph. epidermidis, E. coli, Pseudomonas aeruginosa and Candida albicans
297 when tested according to DIN spec. 91315. The in vitro test showed a mean value of 4.28
298 log levels of germ count reduction. This demonstrates that the disinfection effect of the
299 PLASMOHEAL process is safe under test conditions. Furthermore, the in vivo test based
300 on EN 1500 shows an average reduction performance of 4.82 log levels. This meets both
301 the VAH recommendation of 3 to 5 log levels and the standard alcohol also analyzed as a
302 reference in accordance with EN 1500, which showed a reduction of 4.68 log levels in the
303 current study.

304

305 The initially formulated research question can be answered to the effect that the sufficient
306 germ reduction performance of indirect plasma methods is achieved and that indirect
307 plasma methods in the field of wound decontamination can be regarded as at least

308 equivalent to the effect of direct plasma methods. The claimed effect of direct cold plasma
309 methods is the antimicrobial effect. The use of PLASMOHEAL as a proxy for an indirect
310 method shows the equivalence in the efficacy of indirect methods in relation to the assumed
311 efficacy claim of direct methods. Consequently, the studies of direct cold plasma methods
312 can also be transferred to indirect cold plasma methods as part of a metrological
313 traceability.

314 The energy in the indirect method is only applied in step 1 (Figure 1). As a result, the
315 treatment is painless and non-irritating [9]. By adding the aerosol, a large surface area (up
316 to 10 * 10 cm) can be treated simultaneously within three minutes using the indirect method
317 compared to the direct method.

318

319 The overall view of the results and the additional aspects of wound treatment with indirect
320 plasma methods shows that the tested indirect plasma method can be used in a forward-
321 looking manner in wound treatment, particularly in the case of microbiological colonization.

322 The purpose of the analysis was to determine the microbiocidal effect and its quantification,
323 therefore the analysis focused on these parameters. The consideration of other and
324 secondary parameters is another aspect for future analysis.

325

326 **References**


327 [1] Ehlbeck J, Schnabel U, Polák M, Winter J, Von Woedtke T, Brandenburg R, et al. Low
328 temperature atmospheric pressure plasma sources for microbial decontamination. J Phys
329 D Appl Phys. 2011;44(1):013002. <https://doi.org/10.1088/0022-3727/44/1/013002>.

330 [2] Lerouge S, Wertheimer MR, Yahia L. Plasma Sterilisation: A Review of Parameters,
331 Mechanisms, and Limitations. Plasmas Polym. 2001;6:175-88.
332 <https://doi.org/10.1023/A:1013196629791>.

333 [3] Krömker, W, Schorling, T. Vorrichtung zur Ionisierung von Umgebungsluft [Device for
334 ionising ambient air] (EP 4 175 082 A1). European Patent Office 2023.

- 335 [4] Braný D, Dvorská D, Halašová E, Škovierová H. Cold Atmospheric Plasma: A Powerful
336 Tool for Modern Medicine. *Int J Mol Sci.* 2020;21(8):2932.
337 <https://doi.org/10.3390/ijms21082932>.
- 338 [5] Tischendorf T, Schaal T, Schmelz U. Study on hand disinfection in inpatient geriatric
339 care on the superiority of cold plasma aerosol versus alcohol-based disinfection methods
340 in a parallel group design. *Sci Rep.* 2024 Sep 17;14(1):21703. doi: 10.1038/s41598-024-
341 72524-7. PMID: 39289454; PMCID: PMC11408535.
- 342 [6] Masur K, Schmidt J, Stürmer E, von Woedtke T. Kaltes Plasma zur Heilung chronischer
343 Wunden [Cold plasmas for the healing of chronic wounds]. *WundManagement.*
344 2018;12:253-9.
- 345 [7] Daeschlein G, Napp M, Lutze S, Arnold A, Von Podewils S, Guembel D, et al. Skin and
346 wound decontamination of multidrug-resistant bacteria by cold atmospheric plasma
347 coagulation. *J Ger Dermatol Soc.* 2015;13(2):143-9. <https://doi.org/10.1111/ddg.12559>.
- 348 [8] Zimmermann J, Dumler K, Shimizu T, Morfill GE, Wolf A, Boxhammer V, et al. Effects
349 of cold atmospheric plasmas on adenoviruses in solution. *J Phys D Appl Phys.*
350 2011;44(50):505201. <https://doi.org/10.1088/0022-3727/44/50/505201>.
- 351 [9] Hämmerle G, Ascher S, Gebhardt L. Positive effects of cold atmospheric plasma on pH
352 in wounds: a pilot study. *J Wound Care.* 2023;32(9):530-6.
353 <https://doi.org/10.12968/jowc.2023.32.9.530>.
- 354 [10] Rached NA, Kley S, Storck M, Meyer T, Stücker M. Cold Plasma Therapy in Chronic
355 Wounds-A Multicenter, Randomised Controlled Clinical Trial (Plasma on Chronic Wounds
356 for Epidermal Regeneration Study): Preliminary Results. *J Clin Med.* 2023;12(15):5121.
357 <https://doi.org/10.3390/jcm12155121>.
- 358 [11] Strohal R, Dietrich S, Mittlböck M, Hämmerle G. Chronic wounds treated with cold
359 atmospheric plasmajet versus best practice wound dressings: a multicenter, randomized,
360 non-inferiority trial. *Sci Rep.* 2022;12(1). <https://doi.org/10.1038/s41598-022-07333-x>.
- 361 [12] Stratmann B, Costea TC, Nolte C, Hiller J, Schmidt J, Reindel J, et al. Effect of Cold
362 Atmospheric Plasma Therapy vs Standard Therapy Placebo on Wound Healing in Patients

- 363 With Diabetic Foot Ulcers: A Randomized Clinical Trial. *JAMA Netw Open*. 2020;3(7).
364 <https://doi.org/10.1001/jamanetworkopen.2020.10411>.
- 365 [13] Isbary G, Heinlin J, Shimizu T, Zimmermann J, Morfill G, Schmidt H, et al. Successful
366 and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a
367 randomised controlled trial. *Br J Dermatol*. 2012;167(2):404-10.
368 <https://doi.org/10.1111/j.1365-2133.2012.10923.x>.
- 369 [14] Schachl J, Königshofer M, Stoiber M, Socha M, Grasl C, Abart T, Michel-Behnke I,
370 Wiedemann D, Riebandt J, Zimpfer D, Schlöglhofer T. Cold atmospheric plasma therapy
371 as a novel treatment for Berlin Heart EXCOR pediatric cannula infections. *Artif Organs*.
372 2024. doi: 10.1111/aor.14869.
- 373 [15] Hofmeyer S, Weber F, Gerds S, Emmert S, Thiem A. A Prospective Randomised
374 Controlled Pilot Study to Assess the Response and Tolerability of Cold Atmospheric
375 Plasma for Rosacea. *Skin Pharmacol Physiol*. 2023;36(4):205-13.
376 <https://doi.org/10.1159/000533190>.
- 377 [16] Tomic-Canic M, Burgess JL, O'Neill KE, et al. Skin Microbiota and its Interplay with
378 Wound Healing. *Am J Clin Dermatol*. 2020;21(Suppl 1):36-43.
379 <https://doi.org/10.1007/s40257-020-00536-w>.
- 380 [17] Dunkelberg H, Wedekind S. Eine neue Methode zur Wirksamkeitsprüfung von
381 Sterilgutverpackungen in der Praxis [A new method of testing the effectiveness of sterile
382 packaging in general practice]. *Biomed Tech (Berl)*. 2002;47(11):290-3.
- 383 [18] Disinfectant Commission of the VAH (ed.). Anforderungen und Methoden zur VAH-
384 Zertifizierung chemischer Desinfektionsverfahren [Requirements and methods for VAH
385 certification of chemical disinfection procedures]. Chapters 10-11. Available from:
386 https://vah-online.de/files/download/ebooks/eBook_VAH_Methoden_Anforderungen.pdf.
387 Accessed 2024 Aug 17.




medRxiv preprint doi: <https://doi.org/10.1101/2024.10.12.24315382>; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Figure 2

Comparison of Direct vs. Indirect Cold Plasma Methods


Direct Cold Plasma Method



Indirect Cold Plasma Method




medRxiv preprint doi: <https://doi.org/10.1101/2024.10.12.24315382>; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



medRxiv preprint doi: <https://doi.org/10.1101/2024.10.12.24315382>; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 4



medRxiv preprint doi: <https://doi.org/10.1101/2024.10.12.24315382>; this version posted October 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).